Clinical trial protocol to evaluate the efficacy of cefixime in the treatment of early syphilis
- PDF / 701,446 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 36 Downloads / 195 Views
STUDY PROTOCOL
Open Access
Clinical trial protocol to evaluate the efficacy of cefixime in the treatment of early syphilis Shivani N. Mehta1 , Chrysovalantis Stafylis1, David M. Tellalian2, Pamela L. Burian2, Cliff M. Okada2, Carl E. Millner2, Christopher M. Mejia3 and Jeffrey D. Klausner1,2*
Abstract Background: Syphilis rates have been increasing both in the USA and internationally with incidence higher among men-who-have-sex-with-men and people living with human immunodeficiency virus (HIV) infection. Currently, benzathine penicillin is the recommended treatment for syphilis in all patients. Global shortages and cost increases in benzathine penicillin call for alternative treatment options. This study evaluates the efficacy of oral cefixime for the treatment of early syphilis. Methods: We are conducting a randomized, multisite, open-label, non-comparative clinical trial in Los Angeles and Oakland, CA. Eligible participants are ≥ 18 years old, with primary, secondary, or early latent syphilis (rapid plasma reagin [RPR] titer ≥ 1:8). Patients with HIV infection must have a viral load ≤ 200 copies/mL and CD4+ T cell count ≥ 350 cells/μL during the past 6 months. Participants are randomized to receive either 2.4 M IU benzathine penicillin G intramuscularly once or cefixime 400 mg orally twice a day for 10 days. Participants return at 3, 6, and 12 months post-treatment for follow-up RPR serological testing. The primary outcome is the proportion of participants who achieve ≥ 4-fold RPR titer decrease at 3 or 6 months post-treatment. Discussion: Clinical trials evaluating the efficacy of alternative antibiotics to penicillin are urgently needed. (Continued on next page)
* Correspondence: [email protected] 1 Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA 2 Department of Medicine, AIDS Healthcare Foundation, Los Angeles, CA, USA Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Mehta
Data Loading...
